OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Heldermon on a Phase 1/2 Trial Design of Epidiferphane Plus a Taxane in Breast Cancer

March 12th 2025

Coy Heldermon, MD, PhD, discusses a phase 1/2 trial design evaluating pharmacokinetics and safety of epidiferphane given with taxane chemotherapy in breast cancer.

Dr Moore on Novel ADCs Under Development in FRα+ Ovarian Cancer

March 12th 2025

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies

March 11th 2025

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Dr Garrido-Laguna on the Safety of Daraxonrasib in KRAS G12X–Mutated PDAC

March 11th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses the safety profile of daraxonrasib in patients with KRAS-mutated pancreatic ductal adenocarcinoma

Dr Chiappori on the Integration of Ensartinib Into the NSCLC Treatment Arsenal

March 11th 2025

Alberto Chiappori, MD, discusses the selection between frontline treatment options, including ensartinib, in ALK-positive non–small cell lung cancer.

Dr Melody on the Influence of Female Mentorship on Her Research Career in Hematologic Oncology

March 11th 2025

Megan Melody, MD, discusses the importance of female mentorship on her career development as a hematologist/oncologist.

Dr Davila on ​the Clinical Implications of Tumor Driver and Immune Escape Research in LBCL

March 10th 2025

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Dr Ruella on the Importance of Clinical Trial and Treatment Accessibility for Myeloma

March 10th 2025

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.

Dr Cortese on the Benefits of a Multiomic Evaluation of Immunologic Changes in CLL After Venetoclax

March 10th 2025

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

Dr Richardson on the Role of Triplet Regimens in Newly Diagnosed Myeloma

March 10th 2025

Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.

Dr Bardia on the Importance of HER2 Testing in HER2-Expressing Breast Cancer

March 10th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the need for widespread HER2 testing in patients with HER2-low and -ultralow metastatic breast cancer.

Dr Fakih on the Importance of Genetic Testing in KRAS G12C–Mutant mCRC

March 10th 2025

Marwan G. Fakih, MD, emphasizes the need for next-generation sequencing in colorectal cancer to inform treatment sequencing.

Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

March 8th 2025

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 8th 2025

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

March 7th 2025

Icro Meattini, ​MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Dr Uboha on the FDA Approval of First-Line Tislelizumab Plus Chemotherapy for Metastatic ESCC

March 7th 2025

Nataliya Uboha, MD, PhD, discusses how the FDA approval of tislelizumab plus chemotherapy​ addresses unmet needs for patients with metastatic ESCC.

Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer

March 7th 2025

Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.

Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer

March 7th 2025

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Dr Hinchcliff on the Evolving Role of ADCs in Ovarian Cancer

March 6th 2025

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

Dr Phull on the Rationale for the Retrospective Analysis of CAR T-Cell Therapy in R/R Myeloma

March 6th 2025

Pooja Phull, MD, discusses the rationale for assessing CAR T-cell therapy in the real-world vs trial setting in relapsed/refractory multiple myeloma.

NEXT PAGE
PREVIOUS PAGE